Cyclin D1 in breast cancer

Breast Cancer Research and Treatment

Volumn 52, Issue 1-3, 1998, Pages 1-15

  Barnes, Diana M ^a   Gillett, Cheryl E ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Cyclin D1; Estrogen receptor; p27; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; BREAST CARCINOMA; BREAST DISEASE; BREAST DUCT; BREAST HYPERPLASIA; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE G1 PHASE; GENE AMPLIFICATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C ERB; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0032430697     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006103831990     Document Type: Review

References (69)

1. Bartkova J, Lukas J, Strauss M, Bartek J: Cell cycle related variation and tissue restricted expression of human cyclin D1 protein. J Pathol 172:237-245, 1994
2. Casey G, Smith R, McGillivray D, Peters G, Dickson C: Characterization and chromosome assignment of the human homolog of int-2, a potential proto-oncogene. Mol Cell Biol 6:502-510, 1986
3. Peters G: Inappropriate expression of growth factor genes in tumors induced by mouse mammary tumor virus. Semin Virol 2:319-328, 1991
4. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G: Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer (Letters) 90:43-50, 1995
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
6. Borg Å, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Olsson H, Killander D, McGuire WL: Association of INT2/HST1 co-amplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 63:136-142, 1991
7. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FBJM, Devilee P, Cornelisse CJ, van der Vijver M, Mooi WJ, Michalides RJAM: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52:5229-5234, 1992
8. Fantl V, Richards MA, Smith R, Lammie GA, Johnstone G, Allen D, Gregory W, Peters G, Dickson C, Barnes DM: Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 26:423-429, 1990
9. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444, 1991
10. Schuuring E, Verhofen E, Mooi WJ, Michalides R: Identification and cloning of two over-expressed genes, U21B31/PRAD1 and EMS1, within the amplified 11q13 region in human carcinomas. Oncogene 7:355-361, 1992
11. Gillett CE, Fantl V, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994
12. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993
13. Fantl V, Smith R, Brookes S, Dickson C, Peters G: Chromosome 11q13 abnormalities in human breast cancer. Cancer Surveys 18:77-94, 1993
14. Seshadri R, Lee CSL, Hui R, McCaul K, Horsfall DJ, Sutherland RL: Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2:1177-1184, 1996
15. waf1 immunohistochemical expression. Int J Cancer 74:171-174, 1997
16. Hui R, Cornish AL, McLelland RA, Robertson JFR, Blamey RW, Musgrove EA, Nicholson RI, Sutherland RL: Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 2:923-928, 1996
17. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS: Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1:1257-1260, 1995
18. Zhang S-Y, Caamano J, Cooper F, Guo X, Klein-Szanto AJP: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 102:695-698, 1994
19. Nielsen NH, Emdin SO, Cajander J, Landberg G: Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 14:295-304, 1997
20. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE: Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 151:161-168, 1997
21. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995
22. Evans T, Rosenthal ET, Youngblom J, Distel X, Hunt T: Cyclin: a protein specified by material mRNA in sea urchin eggs that is destroyed at the end of each cell division. Cell 33:389-396, 1983
23. 1 cyclins. Cell 73:1059-1065, 1993
24. Morgan DO: Principles of CDK regulation. Nature 374:131-134, 1995
25. 1 events and regulation of cell proliferation. Science 246:603-608, 1989
26. Peters G: Stifled by inhibitions. Nature 371:204-205, 1994
27. Biggs JR, Kraft AS: Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73:509-514, 1995
28. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
29. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Devel 11:847-862, 1997
30. Zetterberg A, Larsson O, Wiman KG: What is the restriction point? Curr Opin Cell Biol 7:835-842, 1995
31. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385, 1997
32. Assoian RK, Zhu X: Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr Opin Cell Biol 9:93-98, 1997
33. kip1. Genes Devel 11:1464-1478, 1997
34. kip1. EMBO J 16:5334-5344, 1997
35. Juan G, Gong J, Traganos F, Darzynkiewicz Z: Unscheduled expression of cyclins D1 and D3 in human tumour cell lines. Cell Prolif 29:259-266, 1996
36. Sewing A, Burger C, Brusselbach S, Schalk C, Lucibello FC, Muller R: Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP. J Cell Sci 104:545-554, 1993
37. Musgrove EA, Hamilton JA, Lee CSL, Sweeny KJE, Watts CKW, Sutherland RL: Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993
38. Pusch O, Soucek T, Wawra E, Hengstschlager-Ottnad E, Bernaschek G, Hengstschlager M: Specific transformation abolishes cyclin D1 fluctuation throughout the cell cycle. FEBS Lett 385:143-148, 1996
39. Zhu X, Ohtsubo M, Böhmer RM, Roberts JM, Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2 and phosphorylation of the retinoblastoma protein. J Cell Biol 133:391-403, 1996
40. Atadja P, Wong H, Veillete C, Riabowol K: Over-expression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 217:205-216, 1995
41. kip1, inhibits growth and enhances apoptosis. Cell Growth Differ 7:699-710, 1996
42. Lovec H, Sewing A, Lucibello FC, Muller R, Moroy T: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras link between cell cycle and malignant transformation. Oncogene 9:323-326, 1994
43. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocytic maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13:2124-2130, 1994
44. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994
45. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Devel 9:2364-2372, 1995
46. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630, 1995
47. Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361, 1994
48. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9:707-718, 1994
49. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99, 1996
50. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, Sugiura T, Ariyoshi Y, Mitsudomi T, Takahashi T, Takahashi T: Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 3:1051-1058, 1997
51. van Diest P, Michalides RJAM, Jannink I, van der Valk P, Meijer CJLM, Baak JPA: Cyclin D1 expression in invasive breast cancer. Am J Pathol 150:705-711, 1997
52. Müller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M, Strauss M: Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci USA 91:2945-2949, 1994
53. Bates S, Parry D, Bonetta L, Vousden K, Dickson C: Absence of cyclin D/cdk complexes in cells lacking in functional retinoblastoma protein. Oncogene 9:1633-1640, 1994
54. Herwig S, Strauss M: The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur J Biochem 246:581-601, 1997
55. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer (Pred. Oncol.) 79:71-75, 1998
56. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjänen K: Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur J Cancer 31A:329-333, 1995
57. Sutherland RL, Prall OWJ, Alle KM, Wilcken NRC, Hui R, Ball JR, Sarcevic B, Henshall SM, Musgrove EA, Watts CKW: Cyclin-dependent kinases as downstream targets of oestrogen action: potential prognostic indicators and therapeutic targets. Endocrine Related Cancer 4:357-370, 1997
58. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, Ewen ME: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347, 1997
59. Wilcken NRC, Prall OWJ, Musgrove EA, Sutherland RL: Inducible overexpression of cyclin D1 in breast cancer cells reduces the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3:849-854, 1997
60. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-Å, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at APl sites. Science 277:1508-1510, 1997
61. Gillett C, Lee AHS, Barnes DM: Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 184:396-400, 1998
62. Steeg PS, Abrams JS: Cancer prognostics: past, present and p27. Nature Med 3:152-154, 1997
63. kip1 protein: prognostic implications in primary breast cancer. Nature Med 3:227-230, 1997
64. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 3:222-225, 1997
65. 1a,b) invasive breast carcinomas. Cancer Res 57:1259-1263, 1997
66. Zukerberg LR, Yang WI, Gadd M, Thor AD, Koerner FC, Schmidt EV, Arnold A: Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show over-expression of the cyclin D1 oncogene. Modern Pathol 8:560-567, 1995
67. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TWJ, Horne CHW: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891, 1995
68. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J: A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73:728-734, 1996
69. Pelosio P, Barbareschi M, Bonoldi E, Marchetti A, Verderio P, Caffo O, Bevilacqua P, Boracchi P, Buttitta F, Barbazza R, Palma PD, Gasparini G: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol 7:695-705, 1996